Cell cycle proteins and the development of oral squamous cell carcinoma

Murray AW, Hunt T. The Cell Cycle: An Introduction. New York: Freeman, 1993 Nurse P. Universal control mechanism in regulating onset of M-phase. Nature 1990;344:503–508 Reed SI. The role of p34 kinases in the G1 to S-phase transition. Annual Review of Cell Biology 1992;8:529–561 Draetta G, Beach D. Activation of cdk2 protein kinase during mitosis in human cells: cell cycle dependent phosphorylation and subunit arrangement. Cell 1988;54:17 Morla AO, Draetta G, Beach D et al. Reversible tyrosine phosphorylation of cdc2: dephosphorylation accompanies activation during entry into mitosis. Cell 1989;58:193 Buchkovich K, Duffy LA, Harlow E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 1989;58(6):1097–1105 Decaprio JA, Ludlow JW, Lynch D et al. Retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell 1989;58(6):1085–1095 Cordon-Cardo C. Mutation of cell cycle regulators: biological and clinical implications for human neoplasia. Am. J. Pathol. 1995;147(3):547 Goodger NM, Gannon J, Hunt T, Morgan PR. Cell cycle regulatory proteins: an overview with relevance to oral cancer. Oral Oncol. 1997;33(2):61–73 Oswald F, Lovec H, Moroy T, Lipp M. E2F-dependent regulation of human myc: trans-activation by cyclins D1 and A overrides tumour suppressor protein functions. Oncogene 1994; 9:2029–2036 Weinberg R. The retinoblastoma protein and cell cycle control. Cell 1995;81:323–330 Nevins J. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 1992;258:424–429 Orlowski C, Furlanetto R. The mammalian cell cycle in normal and abnormal growth. Endocrinology and Metabolism Clinics of North America 1996;25(3):491–502 Friend SH, Horowitz JM, Gerber MR et al. Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein. Proc. Nat. Acad. Sci. USA 1987;84:9059–9063 Lee WH, Shew JY, Hong FD et al. The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature 1987;329:642–645 Ewen ME, Xing YG, Lawrence JB, Livingston DM. Molecular cloning, chromosomal mapping, and expression of the C-DNA for p107, a retinoblastoma gene product-related protein. Cell 1991;66(6):1155–1164 Hannon GJ, Demetrich D, Beach D. Isolation of the Rb-related p130 through its interaction with CDK2 and cyclins. Genes and Development 1993;7(12A):2378–2381 Ravitz MJ, Wenner CE. cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-β. Advances in Cancer Res. 1997;71:165–207 Pavelic ZP, Lasmar M, Pavleic LJ et al. Absence of retinoblastoma gene product in human primary oral cavity carcinomas. Oral Oncol., Eur. J. Cancer 1996;32B:347–351 Pavelic ZP, Lasmar M, Pavleic LJ et al. Altered expression of retinoblastoma gene in human oral cavity squamous cell carcinoma. Proc. Am. Assoc. of Cancer Res. 1995;36:639 Li YQ, Wang X, Wang J. et al. Loss of heterozygosity on chromosomes 17p13 and 13q14 in head and neck cancer. Proc. Am. Assoc. Cancer Res. 1995;36:229 Yoo GH, Xu HJ, Brennan JA et al. Infrequent inactivation of the retinoblastoma gene despite frequent loss of chromosome 13q in head and neck squamous cell carcinoma. Cancer Res. 1994;54:4603–4606 Kyomoto R, Kumazawa H, Toda Y et al. Cyclin D1 gene amplification is a more potent prognostic factor than its protein over-expression in human head and neck squamous cell carcinoma. Internat. J. Cancer 1997;74:576–581 Meredith SD, Levine PA, Burns JA et al. Chromosome 11q13 amplification in head and neck squamous cell carcinoma: association with poor prognosis. Archives of Otolaryngology Head and Neck Surgery 1995;121(7):790–794 Callender T, El-Naggar AK, Lee MS, Frankenthaler R, Luna MA, Batsakis JG. PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. Cancer 1994;74(1):152–158 Simpson JF, Quan DE, O'Malley F, Odom-Maryon T, Clarke PE. Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. Am. J. Pathol. 1997;151(1):161–168 Fantl V, Richards MA, Smith R et al. Gene amplification on chromosome band 11q13 and oestrogen receptor status in breast cancer. Eur. J. Cancer 1990;26(4):423–429 Lammie GA, Fantl V, Smith RJ, D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to Bcl-1. Oncogene 1991;6:439–444 Peter M., Herskowitz I. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 1994;79:181 Hunter T, Pines J. Cyclins and Cancer, II: cyclin D and CDK inhibitors come of age. Cell 1994;79:573 Harper JW, Adami G, Wei N, Keyomarsi K, Elledge SJ. The 21 kd Cdk interacting protein Cip1 is a potent inhibitor of g1 cyclin dependent kinases. Cell 1993;75:805–816 Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994;78:67–74 Polyak K., Lee M.H. Erdjument-Bromage H., Tempst P., Massague J. Cloning of p27Kip1, a cyclin dependent kinase inhibitor and potential mediator of extracellular antimitogenic signals. Cell 1994;78:59–66 Matsuoka S, Edwards M, Bai C et al. p57Kip2, a structurally distinct member of the p27Cip1 Cdk-inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995;9: 650–662 Lee MH, Reynisdotter I, Massague J. Cloning of p57Kip2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995;9:639–649 Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-β induced cell cycle arrest. Nature 1994;371:257–261 Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/Cdk4. Nature 1993;366:704–707 Guan K, Jenkins CW, Li Y et al. Growth suppression by p18, a p16INK4/MTS1 and p14INK4B/MTS2-related Cdk6 inhibitor, correlates with wild type pRb function. Genes Dev 1994;8:2939–2952 Hirai H, Roussel MF, Kato JY, Ashman RA, Sheer C. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin dependent kinases CDK4 and CDK6. Mol. Cell. Biol. 1995;15:2672–2681 Chan FKM, Zhang J, Cheng L, Shapiro DN, Winoto A. Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16INK4. Mol. Cell. Biol. 1995;15:2682–2688 Hall M, Bates S, Peters G. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 1995; 11:1581–1588 Hussussian CJ, Struewing JP, Goldstein AM et al. Germline p16 mutations in familial melanomas. Nature Genetics 1994;8:15 Kamb A. Cell-cycle regulators and cancer [review]. Trends in Genetics 1995;11:136 Kamb A, Shattuck-Eidens D, Eeles R. Analysis of the p16 gene(CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genetics 1994;8:23 Sheaff RJ, Roberts JM. Lessons in p16 from phylum Falconium. Curr. Biol. 1995;5:28–31 Geradts J, Kratzke RA, Niehans GA, Lincoln CE. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res. 1995;55: 6006–6011 Matsuda H, Konishi N, Hiasa Y et al. Alterations of p16/CDKN2, p53, and ras genes in oral squamous cell carcinomas and premalignant lesions. J. Oral Pathol. Med. 1996;25:232–238 Xiong Y, Hannon GJ, Zhang GJ, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701–704 El-Diery WS, Tokino T, Vleculescu VE et al. WAF1, a potent mediator of p53 tumor suppression. Cell 1993;75:817–825 Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expresssion screen. Exp. Cell Res. 1994;211:90–98 Harper JW, Elledge SJ, Keyomarsi K et al. Inhibition of cyclin-dependent kinases by p21. Mol. Cell. Biol. 1995;6:387–400 Luo y, Hurwitz J, Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 1995;375:159–161 Shiohara M, El-Deiry WS, Wada M et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994; 84:3781–3784 Parker SB, Eichele G, Zhang P et al. p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science 1995;267:1024–1027 El-Deiry WS, Harper JW, O'Connor PM et al. WAF1/Cip1 is induced in p53 mediated G1 arrest and apoptosis. Cancer Res. 1994;4:1169–1174 Dulic V, Kaufman WK, Wilson S et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994;76:1013–1023 Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givoli D. Induction of WAF1/Cip1 by a p53-independent pathway. Cancer Res. 1994;54:3391–3395 Jiang H, Su Z-Z, Collart F, Huberman E, Fisher P. Induction of differentiation in human promyelocytic HL60 leukemia cells activates p21 WAF1/Cip1 expression in the absence of p53. Oncogene 1994;9:3397–3406 Sheikh MS, Garcia M, Zhan Q, Liu Y, Fornace AJ Jr. Cell cycle-independent regulation of p21 WAF1/Cip1 and retinoblastoma protein during okadaic acid-induced apoptosis is coupled with induction of bax protein in human breast carcinoma cells. Cell Growth and Differentiation 1996;7:1599–1607 Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351(6326):453–6 Ryan JJ, Danish R, Gottleib CA, Clarke MF. Cell cycle analysis of p53-induced cell death in murine erythroleukemia cells. Mol. Cell. Biol. 1993;13(1):711–19 Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88(3):323–31 Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, Rasking WH, Reid BJ. A p53-dependent mouse spindle checkpoint. Science 1995;267(5202):1353–6 Miyashita T, Harigai M, Hanada M, Reed JC, Identification of a p53- dependent negative response element in the bcl-2 gene. Cancer Res. 1994;54(12):3131–5 Polyak K, Kato J-Y, Solomon MJ et al. p27Kip1, a cyclin-CDK inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 1994;8:9–22 Jordan RCK, Bradley G, Slingerland J. Reduced levels of the cell-cycle inhibitor p27Kip1 in epithelial dysplasia and carcinoma of the oral cavity. Am. J. Pathol. 1998;152(2):585–589 Ponce-Castenada MV, Lee M-H, Latres E et al. p27Kip1, chromosomal mapping to 12p12–12p13.1 and absence of mutations in human tumors. Cancer Res. 1995;55:1211–1214 Pavelic ZP, Lasmar M, Pavelic LJ et al. Absence of retinoblastoma gene product in human primary oral cavity carcinomas. Oral Oncol., Eur. J. Cancer 1996;32B:347–351 Yokoyama J, Shiga K, Suzuki M, Takasaka T. Abnormalities and the implication of retinoblastoma locus and its protein product in head and neck cancers. Anticancer Res. 1996;16(2):641–644 Maestro R, Piccinin S, Doglioni C et al. Chromosome 13q deletion mapping in head and neck squamous cell carcinoma: identification of two distinct regions of preferential loss. Cancer Res. 1996;56(5):1146–1150 Andl T, Kahn T, Pfuhl A et al. Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res. 1998;58(1):5–13 Gimenez-Conti IB, Collet AM, Lanfranchi H et al. p53, Rb, and cyclin D1 expression in human oral verrucous carcinomas. Cancer 1996;78(1):17–23 Gope R, Christensen MA, Thorson A et al. Increased expression of the retinoblastoma gene in human colorectal carcinomas relative to normal colonic mucosa. J. Nat. Cancer Institute 1990;82(4):310–314 Ali AA, Harvey JP, Wildrick DM, Boman BM. Retinoblastoma gene product-associated proteins in human colon cancer cell lines. Biochem. and Biophys. Res. Commun. 1993;194:848–854 Yamamato H, Monden T, Ikeda K et al. Coexpression of cdk2/cdc2 and retinoblastoma gene products in colorectal cancer. British J. Cancer 1995;71:1231–1236 Xu HJ, Hu SX, Benedict WF, Lack of nuclear RB protein staining in G0/middle G1 cells: correlation to changes in total RB protein level. Oncogene 1991;6(7):1139–1146 Haupt Y, Rowan S, Shaulian E, Vousden KH, Oren M. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev 1995;9(17):2170–2183 Morgenbesser SD, Williams BO, Jacks T, DePinho RA. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens [see comments]. Nature 1994;371:72–74 Qin XQ, Livingston DM, Kaelin WG Jr, Adams PD. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc. Nat. Acad. Sci. USA 1994; 91:10918–10922 Shimizu E, Coxon A, Ottersen GA, et al. Rb protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene 1994;9:2441 Geradts J, Kratzke RA, Crush-Stanton S, Wen SF, Lincoln CE. Wild type and mutant retinoblastoma protein in paraffin sections. Modern Pathol. 1996;9:339–347 Poluha W, Poluha DK, Chang B et al. The cyclin-dependent kinase inhibitor p21 (WAF1) is require for survival of differentiating neuroblastoma cells. Mol. Cell. Biol. 1996;16:135–1341 Wang J, Walsh K, Resistance to apoptosis conferred by cdk inhibitors during myocyte differentiation. Science 1996;273: 359-361 Hiyama H, Iavarone A, LaBaer J, Reeves SA. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression. Oncogene 1997;14(21):2533–42 LaBaer J, Garret MD, Stevenson LF et al. New functional activities for the p21 family of cdk inhibitors. Genes and Development 1997;11(7):847–62 Erber R, Klein W, Andl T et al. Aberrant p21(CIP1/WAF1) protein accumulation in head-and-neck cancer. Internat. J. Cancer 1997;74(4):383–9 Cordon-Cardo C. Mutation of cell cycle regulators: biological and clinical implications for human neoplasia. Am. J. Pathol. 1995;147(3):551 Qian W, Hu L-F, Chen F et al. Infrequent MDM2 gene amplification and absence of gross WAF1 gene alterations in nasopharyngeal carcinoma. Oral Oncol., Eur. J. Cancer 1995;31B:328–332 Shiohara M, El-Deiry WS, Wada M et al. Absence of waf1 mutations in a variety of human malignancies. Blood 1994;84:3781–3784 Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givoli D. Induction of WAF1/Cip1 by a p53-independent pathway. Cancer Res. 1994;54:3391–3395 Steinman RA, Hoffman B, Iro A et al. Induction of p21 (Waf1/Cip1) during differentiation. Oncogene 1994;9:3389–3396 Zhang W, Grasso L, McClain CD et al. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res. 1995;55:668–674 Cordon-Cardo C. Mutation of cell cycle regulators: biological and clinical implications for human neoplasia. Amer. J. Pathol. 1995;147(3):552 Ponce-Castenada MV, Lee M-H, Latres E et al. p27Kip1, chromosomal mapping to 12p12–12p13.1 and absence of mutations in human tumors. Cancer Res. 1995;55:1211–1214 Pietenpol JA, Bohlander SK, Sato Y et al. Assignment of human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res. 1995;55:1206–1210 Bullrich F, Machlachan TK, Sang N et al. Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE and PITALRE and a cdk inhibitor, p27Kip1, to regions involved in human cancer. Cancer Res. 1995;55:199–1205